Updated on 2023/12/01

写真a

 
YAMAGUCHI Junpei
 
Organization
Nagoya University Hospital Associate professor of hospital
Title
Associate professor of hospital

Degree 1

  1. 博士(医学) ( 2009.9   名古屋大学 ) 

Research Interests 1

  1. pancreatic cancer

Research Areas 1

  1. Life Science / General surgery and pediatric surgery

Research History 11

  1. Nagoya University

    2014.4

  2. 大垣市民病院外科 医長

    2013.4 - 2014.3

      More details

    Country:Japan

  3. Massachusetts General Hospital, Surgery Division, Research Fellow

    2010.4 - 2013.3

      More details

    Country:United States

  4. 名古屋大学医学部腫瘍外科 医員

    2009.4 - 2010.3

      More details

    Country:Japan

  5. 金沢大学医学系研究科形態機能病理学 客室研究員

    2007.4 - 2009.3

      More details

    Country:Japan

  6. 愛知県厚生連安城更生病院 外科医師

    2006.6 - 2007.3

      More details

    Country:Japan

  7. 国立がんセンター中央病院 外科レジデント

    2003.6 - 2006.5

      More details

    Country:Japan

  8. 名古屋大学医学部付属病院器官調節外科 医員

    2003.5

      More details

    Country:Japan

  9. 岐阜厚生連久美愛病院 外科医師

    2002.4 - 2003.4

      More details

    Country:Japan

  10. 社会保険中京病院 嘱託専攻医

    2000.4 - 2002.3

      More details

    Country:Japan

  11. 社会保険中京病院 臨床研修医

    1998.5 - 2000.3

      More details

    Country:Japan

▼display all

 

Papers 107

  1. TREFOIL FACTOR FAMILY 1 INHIBITS THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA BY REGULATING B-CATENIN ACTIVATION

    Ochiai Yosuke, Yamaguchi Junpei, Kokuryo Toshio, Yokoyama Yukihiro, Ebata Tomoki, Nagino Masato

    HEPATOLOGY   Vol. 70   page: 1196A - 1196A   2019.10

     More details

  2. Trefoil factor 1 inhibits epithelial-mesenchymal transition of pancreatic intraepithelial neoplasm

    Yamaguchi Junpei, Yokoyama Yukihiro, Kokuryo Toshio, Ebata Tomoki, Enomoto Atsushi, Nagino Masato

    JOURNAL OF CLINICAL INVESTIGATION   Vol. 128 ( 8 ) page: 3619 - 3629   2018.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1172/JCI97755

    Web of Science

    PubMed

  3. Loss of Trefoil Factor Family 2 from pancreatic duct glands promotes formation of intraductal papillary mucinous neoplasms in mice Reviewed

    Junpei Yamaguchi, Mari Mino-Kenudson, Andrew S. Liss, Sanjib Chowdhury, Timothy C. Wang, Carlos Fernández-del Castillo, Keith D. Lillemoe, Andrew L. Warshaw, and Sarah P. Thayer

      Vol. 151 ( 6 ) page: 1232-1244   2016

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  4. Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer.

    Nakajima H, Yamaguchi J, Takami H, Hayashi M, Kodera Y, Nishida Y, Watanabe N, Onoe S, Mizuno T, Yokoyama Y, Ebata T

    International journal of clinical oncology     2023.3

     More details

    Language:English  

    DOI: 10.1007/s10147-023-02321-1

    PubMed

  5. Early Prediction of a Serious Postoperative Course in Perihilar Cholangiocarcinoma: Trajectory Analysis of the Comprehensive Complication Index.

    Kawakatsu S, Yamaguchi J, Mizuno T, Watanabe N, Onoe S, Igami T, Yokoyama Y, Uehara K, Nagino M, Matsuo K, Ebata T

    Annals of surgery   Vol. 277 ( 3 ) page: 475 - 483   2023.3

     More details

    Language:English  

    DOI: 10.1097/SLA.0000000000005162

    PubMed

  6. Efficacy of Extended Modification in Left Hemihepatectomy for Advanced Perihilar Cholangiocarcinoma: Comparison Between H12345'8'-B-MHV and H1234-B.

    Otsuka S, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Shimoyama Y, Igami T, Uehara K, Yokoyama Y, Nagino M, Ebata T

    Annals of surgery   Vol. 277 ( 3 ) page: e585 - e591   2023.3

     More details

    Language:English  

    DOI: 10.1097/SLA.0000000000005248

    PubMed

  7. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer.

    Kano MT, Kokuryo T, Baba T, Yamazaki K, Yamaguchi J, Sunagawa M, Ogura A, Watanabe N, Onoe S, Miyata K, Mizuno T, Uehara K, Igami T, Yokoyama Y, Ebata T, Nagino M

    Anticancer research   Vol. 43 ( 3 ) page: 1009 - 1016   2023.3

     More details

    Language:English  

    DOI: 10.21873/anticanres.16245

    PubMed

  8. Which modality is better to diagnose high-grade transformation in retroperitoneal liposarcoma? Comparison of computed tomography, positron emission tomography, and magnetic resonance imaging.

    Nakashima Y, Yokoyama Y, Ogawa H, Sakakibara A, Sunagawa M, Nishida Y, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Kawakatsu S, Igami T, Ebata T

    International journal of clinical oncology   Vol. 28 ( 3 ) page: 482 - 490   2023.3

     More details

    Language:English  

    DOI: 10.1007/s10147-022-02287-6

    PubMed

  9. Impact of preoperative muscle mass and quality on surgical outcomes in patients undergoing major hepatectomy for perihilar cholangiocarcinoma.

    Asai Y, Yamaguchi J, Mizuno T, Onoe S, Watanabe N, Igami T, Uehara K, Yokoyama Y, Ebata T

    Journal of hepato-biliary-pancreatic sciences   Vol. 30 ( 2 ) page: 202 - 211   2023.2

     More details

    Language:English  

    DOI: 10.1002/jhbp.1220

    PubMed

  10. Antitumor Effects of Deep Ultraviolet Irradiation for Pancreatic Cancer.

    Yamazaki K, Kokuryo T, Yamaguchi J, Sunagawa M, Ogura A, Watanabe N, Onoe S, Miyata K, Mizuno T, Uehara K, Igami T, Yokoyama Y, Ebata T, Nagino M

    Anticancer research   Vol. 43 ( 2 ) page: 621 - 630   2023.2

     More details

    Language:English  

    DOI: 10.21873/anticanres.16198

    PubMed

  11. Minimum radial margin in pelvic exenteration for locally advanced or recurrent rectal cancer.

    Aiba T, Uehara K, Tsuyuki Y, Ogura A, Murata Y, Mizuno T, Yamaguchi J, Kokuryo T, Yokoyama Y, Ebata T

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology   Vol. 48 ( 12 ) page: 2502 - 2508   2022.12

     More details

    Language:English  

    DOI: 10.1016/j.ejso.2022.06.015

    PubMed

  12. Early volume loss of skeletal muscle after esophagectomy: a risk for late-onset postoperative pneumonia.

    Nishimura K, Miyata K, Fukaya M, Yokoyama Y, Uehara K, Yamaguchi J, Mizuno T, Onoe S, Ogura A, Ebata T

    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus   Vol. 35 ( 11 )   2022.11

     More details

    Language:English  

    DOI: 10.1093/dote/doac019

    PubMed

  13. Is a specific T classification needed for extrahepatic intraductal papillary neoplasm of the bile duct (IPNB) type 2 associated with invasive carcinoma?

    Mitake Y, Onoe S, Igami T, Mizuno T, Yamaguchi J, Sunagawa M, Watanabe N, Kawakatsu S, Shimoyama Y, Ebata T

    Journal of hepato-biliary-pancreatic sciences     2022.11

     More details

    Language:English  

    DOI: 10.1002/jhbp.1269

    PubMed

  14. A proposal of drain removal criteria in hepatobiliary resection.

    Watanabe N, Mizuno T, Yamaguchi J, Yokoyama Y, Igami T, Onoe S, Uehara K, Sunagawa M, Ebata T

    Journal of hepato-biliary-pancreatic sciences   Vol. 29 ( 9 ) page: 974 - 982   2022.9

     More details

    Language:English  

    DOI: 10.1002/jhbp.1194

    PubMed

  15. Trefoil factor 1 inhibits the development of esophageal adenocarcinoma from Barrett's epithelium.

    Hasebe K, Yamazaki K, Yamaguchi J, Kokuryo T, Yokoyama Y, Miyata K, Fukaya M, Nagino M, Ebata T

    Laboratory investigation; a journal of technical methods and pathology   Vol. 102 ( 8 ) page: 885 - 895   2022.8

     More details

    Language:English  

    DOI: 10.1038/s41374-022-00771-1

    PubMed

  16. Mild Prognostic Impact of Postoperative Complications on Long-term Survival of Perihilar Cholangiocarcinoma.

    Kawakatsu S, Ebata T, Watanabe N, Onoe S, Yamaguchi J, Mizuno T, Igami T, Yokoyama Y, Matsuo K, Nagino M

    Annals of surgery   Vol. 276 ( 1 ) page: 146 - 152   2022.7

     More details

    Language:English  

    DOI: 10.1097/SLA.0000000000004465

    PubMed

  17. Superiority of clinical American Joint Committee on Cancer T classification for perihilar cholangiocarcinoma.

    Yamada M, Mizuno T, Yamaguchi J, Yokoyama Y, Igami T, Onoe S, Watanabe N, Uehara K, Matsuo K, Ebata T

    Journal of hepato-biliary-pancreatic sciences   Vol. 29 ( 7 ) page: 768 - 777   2022.7

     More details

    Language:English  

    DOI: 10.1002/jhbp.1066

    PubMed

  18. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).

    Yamaguchi J, Yokoyama Y, Fujii T, Yamada S, Takami H, Kawashima H, Ohno E, Ishikawa T, Maeda O, Ogawa H, Kodera Y, Nagino M, Ebata T

    Annals of surgery   Vol. 275 ( 6 ) page: 1043 - 1049   2022.6

     More details

    Language:English  

    DOI: 10.1097/SLA.0000000000005430

    PubMed

  19. Combined Vascular Resection for Locally Advanced Perihilar Cholangiocarcinoma.

    Mizuno T, Ebata T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Kamei Y, Nagino M

    Annals of surgery   Vol. 275 ( 2 ) page: 382 - 390   2022.2

     More details

    Language:English  

    DOI: 10.1097/SLA.0000000000004322

    PubMed

  20. A long-term survivor of advanced retroperitoneal dedifferentiated liposarcoma: a successful multimodal approach with extended resection and chemotherapy.

    Nakahashi K, Yokoyama Y, Fukaya M, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Ebata T

    Nagoya journal of medical science   Vol. 84 ( 1 ) page: 200 - 207   2022.2

     More details

    Language:English  

    DOI: 10.18999/nagjms.84.1.200

    PubMed

  21. Predicting Inchinkoto efficacy, in patients with obstructive jaundice associated with malignant tumors, through pharmacomicrobiomics.

    Yamashita H, Nishiyama M, Ohbuchi K, Kanno H, Tsuchiya K, Yamaguchi J, Mizuno T, Ebata T, Nagino M, Yokoyama Y

    Pharmacological research   Vol. 175   page: 105981   2022.1

     More details

    Language:English  

    DOI: 10.1016/j.phrs.2021.105981

    PubMed

  22. Trefoil factor family 2 inhibits cholangiocarcinogenesis by regulating the PTEN pathway in mice.

    Hasebe K, Yamaguchi J, Kokuryo T, Yokoyama Y, Ochiai Y, Nagino M, Ebata T

    Carcinogenesis   Vol. 42 ( 12 ) page: 1496 - 1505   2021.12

     More details

    Language:English  

    DOI: 10.1093/carcin/bgab093

    PubMed

  23. A clinicopathological reappraisal of intraductal papillary neoplasm of the bile duct (IPNB): a continuous spectrum with papillary cholangiocarcinoma in 181 curatively resected cases.

    Onoe S, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Watanabe N, Otsuka S, Nakamura S, Shimoyama Y, Nagino M

    HPB : the official journal of the International Hepato Pancreato Biliary Association   Vol. 23 ( 10 ) page: 1525 - 1532   2021.10

     More details

    Language:English  

    DOI: 10.1016/j.hpb.2021.03.004

    PubMed

  24. [Ⅱ.Treatment for Recurrent Cholangiocarcinoma].

    Watanabe N, Yokoyama Y, Igami T, Uehara K, Mizuno T, Yamaguchi J, Miyata K, Onoe S, Ogura A, Ebata T

    Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 48 ( 10 ) page: 1223 - 1226   2021.10

     More details

    Language:Japanese  

    PubMed

  25. Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis.

    Takahashi D, Mizuno T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Maeda O, Ando M, Ebata T

    Journal of hepato-biliary-pancreatic sciences   Vol. 28 ( 9 ) page: 716 - 726   2021.9

     More details

    Language:English  

    DOI: 10.1002/jhbp.1005

    PubMed

  26. A presurgical prognostic stratification based on nutritional assessment and carbohydrate antigen 19-9 in pancreatic carcinoma: An approach with nonanatomic biomarkers.

    Onoe S, Yokoyama Y, Kokuryo T, Igami T, Mizuno T, Yamaguchi J, Watanabe N, Kawakatsu S, Ebata T

    Surgery   Vol. 169 ( 6 ) page: 1463 - 1470   2021.6

     More details

    Language:English  

    DOI: 10.1016/j.surg.2020.11.035

    PubMed

  27. Hepatopancreatoduodenectomy with simultaneous resection of the portal vein and hepatic artery for locally advanced cholangiocarcinoma: Short- and long-term outcomes of superextended surgery.

    Nagino M, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N

    Journal of hepato-biliary-pancreatic sciences   Vol. 28 ( 4 ) page: 376 - 386   2021.4

     More details

    Language:English  

    DOI: 10.1002/jhbp.914

    PubMed

  28. A Study on Radial Margin Status in Resected Perihilar Cholangiocarcinoma.

    Shinohara K, Ebata T, Shimoyama Y, Mizuno T, Yokoyama Y, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    Annals of surgery   Vol. 273 ( 3 ) page: 572 - 578   2021.3

     More details

  29. Application of fluorescent cholangiography during single-incision laparoscopic cholecystectomy in the cystohepatic duct without preoperative diagnosis.

    Asai Y, Igami T, Ebata T, Yokoyama Y, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    ANZ journal of surgery   Vol. 91 ( 3 ) page: 470 - 472   2021.3

     More details

  30. Impact of Preoperative Occult-Bacterial Translocation on Surgical Site Infection in Patients Undergoing Pancreatoduodenectomy.

    Suenaga M, Yokoyama Y, Fujii T, Yamada S, Yamaguchi J, Hayashi M, Asahara T, Nagino M, Kodera Y

    Journal of the American College of Surgeons   Vol. 232 ( 3 ) page: 298 - 306   2021.3

     More details

  31. Premalignant pancreatic cells seed stealth metastasis in distant organs in mice.

    Yamaguchi J, Kokuryo T, Yokoyama Y, Ebata T, Ochiai Y, Nagino M

    Oncogene   Vol. 40 ( 12 ) page: 2273 - 2284   2021.3

     More details

    Language:English  

    DOI: 10.1038/s41388-021-01706-8

    PubMed

  32. Impact of the preoperative body composition indexes on intraoperative blood loss in patients undergoing pancreatoduodenectomy.

    Ishii K, Yokoyama Y, Ebata T, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    Surgery today   Vol. 51 ( 1 ) page: 52 - 60   2021.1

     More details

  33. Impact of Perioperative Steroid Administration in Patients Undergoing Major Hepatectomy with Extrahepatic Bile Duct Resection: A Randomized Controlled Trial.

    Onoe S, Yokoyama Y, Ebata T, Igami T, Mizuno T, Yamaguchi J, Watanabe N, Suzuki S, Nishiwaki K, Ando M, Nagino M

    Annals of surgical oncology   Vol. 28 ( 1 ) page: 121 - 130   2021.1

     More details

  34. Impact of Qualitative and Quantitative Biliary Contamination Status on the Incidence of Postoperative Infection Complications in Patients Undergoing Pancreatoduodenectomy.

    Suenaga M, Yokoyama Y, Fujii T, Yamada S, Yamaguchi J, Hayashi M, Asahara T, Nagino M, Kodera Y

    Annals of surgical oncology   Vol. 28 ( 1 ) page: 560 - 569   2021.1

     More details

  35. The influence of the preoperative thickness of the abdominal cavity on the gastrojejunal anatomic position and delayed gastric emptying after pancreatoduodenectomy.

    Watanabe N, Yokoyama Y, Ebata T, Igami T, Mizuno T, Yamaguchi J, Onoe S, Nagino M

    HPB : the official journal of the International Hepato Pancreato Biliary Association   Vol. 22 ( 12 ) page: 1695 - 1702   2020.12

     More details

  36. Study of the Portal Branches Arising from the Cranial Part of the Umbilical Portion of the Left Portal Vein: Implications for Anatomic Right Hepatic Trisectionectomy.

    Minami T, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    World journal of surgery   Vol. 44 ( 12 ) page: 4231 - 4235   2020.12

     More details

  37. How long should follow-up be continued after R0 resection of perihilar cholangiocarcinoma?

    Nakahashi K, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    Surgery   Vol. 168 ( 4 ) page: 617 - 624   2020.10

     More details

  38. Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preoperative therapy.

    Yamada S, Yokoyama Y, Sonohara F, Yamaguchi J, Takami H, Hayashi M, Onoe S, Fujii T, Nagino M, Kodera Y

    Journal of hepato-biliary-pancreatic sciences   Vol. 27 ( 8 ) page: 487 - 495   2020.8

     More details

  39. Trefoil Factor Family 1 Inhibits the Development of Hepatocellular Carcinoma by Regulating β-Catenin Activation.

    Ochiai Y, Yamaguchi J, Kokuryo T, Yokoyama Y, Ebata T, Nagino M

    Hepatology (Baltimore, Md.)   Vol. 72 ( 2 ) page: 503 - 517   2020.8

     More details

  40. Postoperative infectious complications caused by multidrug-resistant pathogens in patients undergoing major hepatectomy with extrahepatic bile duct resection.

    Sugawara G, Yokoyama Y, Ebata T, Igami T, Yamaguchi J, Mizuno T, Onoe S, Watanabe N, Nagino M

    Surgery   Vol. 167 ( 6 ) page: 950 - 956   2020.6

     More details

  41. Study on the Segmentation of the Right Posterior Sector of the Liver.

    Minami T, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    World journal of surgery   Vol. 44 ( 3 ) page: 896 - 901   2020.3

     More details

  42. Predictive performance of Blumgart T staging for perihilar cholangiocarcinoma in a Japanese center.

    Ebata T, Mizuno T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    Journal of hepato-biliary-pancreatic sciences   Vol. 27 ( 3 ) page: 132 - 140   2020.3

     More details

  43. Postoperative Pancreatic Fistula in Surgery for Perihilar Cholangiocarcinoma.

    Watanabe N, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Nagino M

    World journal of surgery   Vol. 43 ( 12 ) page: 3094 - 3100   2019.12

     More details

  44. A case of small in situ perihilar cholangiocarcinoma incidentally accompanied by benign bile duct stricture after open cholecystectomy.

    Maeda T, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    Surgical case reports   Vol. 5 ( 1 ) page: 177   2019.11

     More details

  45. Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis.

    Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, Esaki N, Ushida K, Mii S, Shiraki Y, Ando K, Weng L, Ishihara S, Ponik SM, Conklin MW, Haga H, Nagasaka A, Miyata T, Matsuyama M, Kobayashi T, Fujii T, Yamada S, Yamaguchi J, Wang T, Woods SL, Worthley D, Shimamura T, Fujishiro M, Hirooka Y, Enomoto A, Takahashi M

    Cancer research   Vol. 79 ( 20 ) page: 5367 - 5381   2019.10

     More details

  46. Discrepancy between volume and functional recovery in early phase liver regeneration following extended hepatectomy with extrahepatic bile duct resection.

    Maeda T, Yokoyama Y, Ebata T, Igami T, Mizuno T, Yamaguchi J, Onoe S, Ando M, Nagino M

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 49 ( 10 ) page: 1227 - 1235   2019.10

     More details

  47. Benign hilar bile duct strictures resected as perihilar cholangiocarcinoma.

    Otsuka S, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Shimoyama Y, Nagino M

    The British journal of surgery   Vol. 106 ( 11 ) page: 1504 - 1511   2019.10

     More details

  48. Occult synchronous liver metastasis from perihilar cholangiocarcinoma.

    Ohiwa T, Ebata T, Mizuno T, Yokoyama Y, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    Surgery   Vol. 166 ( 3 ) page: 290 - 296   2019.9

     More details

  49. Cholangiographic Tumor Classification for Simple Patient Selection Prior to Hepatopancreatoduodenectomy for Cholangiocarcinoma.

    Toyoda Y, Ebata T, Mizuno T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    Annals of surgical oncology   Vol. 26 ( 9 ) page: 2971 - 2979   2019.9

     More details

  50. Preoperative course of patients undergoing endoscopic nasobiliary drainage during the management of resectable perihilar cholangiocarcinoma.

    Maeda T, Ebata T, Yokoyama Y, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Kawashima H, Nagino M

    Journal of hepato-biliary-pancreatic sciences   Vol. 26 ( 8 ) page: 341 - 347   2019.8

     More details

  51. Left trisectionectomy combined with resection of the right hepatic vein and inferior vena cava after right hepatic vein embolization for advanced intrahepatic cholangiocarcinoma.

    Suzuki T, Ebata T, Yokoyama Y, Mizuno T, Igami T, Yamaguchi J, Onoe S, Watanabe N, Nagino M

    Surgical case reports   Vol. 5 ( 1 ) page: 98   2019.6

     More details

  52. Is constant negative pressure for external drainage of the main pancreatic duct useful in preventing pancreatic fistula following pancreatoduodenectomy?

    Sunagawa M, Yokoyama Y, Yamaguchi J, Ebata T, Sugawara G, Igami T, Mizuno T, Nagino M

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]   Vol. 19 ( 4 ) page: 602 - 607   2019.6

     More details

  53. Pleural dissemination of cholangiocarcinoma caused by percutaneous transhepatic biliary drainage during the management of resectable cholangiocarcinoma.

    Yamashita H, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Ando M, Nagino M

    Surgery   Vol. 165 ( 5 ) page: 912 - 917   2019.5

     More details

  54. NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies.

    Kokuryo T, Yokoyama Y, Yamaguchi J, Tsunoda N, Ebata T, Nagino M

    Anticancer research   Vol. 39 ( 5 ) page: 2251 - 2258   2019.5

     More details

  55. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study.

    Takano N, Yamada S, Hirakawa A, Yokoyama Y, Kawashima H, Maeda O, Okada T, Ohno E, Yamaguchi J, Ishikawa T, Sonohara F, Suenaga M, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y, Naganawa S, Ando Y, Nagino M, Goto H, Fujii T, Kodera Y

    Nagoya journal of medical science   Vol. 81 ( 2 ) page: 233 - 239   2019.5

     More details

  56. Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer.

    Mizuno T, Ebata T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Ando M, Nagino M

    The British journal of surgery   Vol. 106 ( 5 ) page: 626 - 635   2019.4

     More details

  57. A case of human pancreatic eurytremiasis.

    Ogawa H, Takehara Y, Naganawa S, Yamaguchi J, Nakaguro M

    Abdominal radiology (New York)   Vol. 44 ( 4 ) page: 1213 - 1216   2019.4

     More details

    Language:English  

    DOI: 10.1007/s00261-019-01925-4

    PubMed

  58. Pharmacokinetics of Nek2 siRNA in Peritoneal Dissemination of Pancreatic Cancer

    Kokuryo T., Yamaguchi J., Yokoyama Y., Nagino M.

    PANCREAS   Vol. 48 ( 10 ) page: 1465 - 1465   2019

     More details

  59. Trefoil Factor Family 1 (TFF1) Inhibits Epithelial-mesenchymal Transition and Enhances the Chemosensitivity of Pancreatic Ductal Adenocarcinoma (PDAC)

    Yamaguchi J., Kokuryo T., Yokoyama Y., Ebata T., Nagino M.

    PANCREAS   Vol. 48 ( 10 ) page: 1551 - 1552   2019

     More details

  60. Anti-tumor Effects of Deep Ultraviolet Irradiation for Pancreas Cancer

    Yamazaki K., Kokuryo T., Yamaguchi J., Yokoyama Y., Nagino M.

    PANCREAS   Vol. 48 ( 10 ) page: 1553 - 1553   2019

     More details

  61. Comparison between autologous and homologous blood transfusions in liver resection for biliary tract cancer: a propensity score matching analysis.

    Onoe S, Yokoyama Y, Ebata T, Igami T, Mizuno T, Yamaguchi J, Watanabe N, Nagino M

    Journal of hepato-biliary-pancreatic sciences   Vol. 25 ( 12 ) page: 550 - 559   2018.12

     More details

  62. Loss of trefoil factor 1 inhibits biliary regeneration but accelerates the hepatic differentiation of progenitor cells in mice.

    Hayashi Y, Yamaguchi J, Kokuryo T, Ebata T, Yokoyama Y, Nagino M

    Biochemical and biophysical research communications   Vol. 506 ( 1 ) page: 12 - 19   2018.11

     More details

  63. Surgery for perihilar cholangiocarcinoma from a viewpoint of age: Is it beneficial to octogenarians in an aging society?

    Akashi K, Ebata T, Mizuno T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Nagino M

    Surgery   Vol. 164 ( 5 ) page: 1023 - 1029   2018.11

     More details

  64. Application of three-dimensional print in minor hepatectomy following liver partition between anterior and posterior sectors.

    Igami T, Nakamura Y, Oda M, Tanaka H, Nojiri M, Ebata T, Yokoyama Y, Sugawara G, Mizuno T, Yamaguchi J, Mori K, Nagino M

    ANZ journal of surgery   Vol. 88 ( 9 ) page: 882 - 885   2018.9

     More details

  65. Ethanol ablation for refractory bile leakage after complex hepatectomy.

    Ito A, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Nagino M

    The British journal of surgery   Vol. 105 ( 8 ) page: 1036 - 1043   2018.7

     More details

  66. Application of fluorescent cholangiography during single-incision laparoscopic cholecystectomy for cholecystitis with a right-sided round ligament: Preliminary experience.

    Nojiri M, Igami T, Toyoda Y, Ebata T, Yokoyama Y, Sugawara G, Mizuno T, Yamaguchi J, Nagino M

    Journal of minimal access surgery   Vol. 14 ( 3 ) page: 244 - 246   2018.7

     More details

  67. Preoperative biliary colonization/infection caused by multidrug-resistant (MDR) pathogens in patients undergoing major hepatectomy with extrahepatic bile duct resection.

    Sugawara G, Yokoyama Y, Ebata T, Igami T, Yamaguchi J, Mizuno T, Yagi T, Nagino M

    Surgery   Vol. 163 ( 5 ) page: 1106 - 1113   2018.5

     More details

  68. Impact of the gastrojejunal anatomic position as the mechanism of delayed gastric emptying after pancreatoduodenectomy.

    Nojiri M, Yokoyama Y, Maeda T, Ebata T, Igami T, Sugawara G, Yamaguchi J, Nagino M

    Surgery   Vol. 163 ( 5 ) page: 1063 - 1070   2018.5

     More details

  69. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.

    Yamada S, Fujii T, Yokoyama Y, Kawashima H, Maeda O, Suzuki K, Okada T, Ono E, Yamaguchi J, Takano N, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y, Naganawa S, Ando Y, Nagino M, Goto H, Kodera Y

    Cancer chemotherapy and pharmacology   Vol. 81 ( 5 ) page: 815 - 821   2018.5

     More details

  70. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach.

    Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M

    Surgery   Vol. 163 ( 4 ) page: 732 - 738   2018.4

     More details

  71. Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer.

    Baba T, Kokuryo T, Yamaguchi J, Yokoyama Y, Uehara K, Ebata T, Nagino M

    Anticancer research   Vol. 38 ( 3 ) page: 1427 - 1434   2018.3

     More details

  72. Inhibition of Toll-like receptor 4 ameliorates experimental postischemic injury in the cholestatic liver through inhibition of high-mobility group box protein b1 (HMGB1) signaling.

    Yokoi T, Yokoyama Y, Kokuryo T, Yamaguchi J, Nagino M

    Surgery   Vol. 163 ( 2 ) page: 270 - 276   2018.2

     More details

  73. Does the intestinal microenvironment have an impact on the choleretic effect of inchinkoto, a hepatoprotective herbal medicine?

    Uji M, Yokoyama Y, Asahara T, Ebata T, Igami T, Mizuno T, Yamaguchi J, Nagino M

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 48 ( 3 ) page: E303 - E310   2018.2

     More details

  74. Cells of Origin of Pancreatic Neoplasms Reviewed

    Yamaguchi J, Yokoyama Y, Kokuryo T, Ebata T, Nagino M.

    Surgery Today   Vol. 48 ( 1 ) page: 9-17   2018.1

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  75. Cells of origin of pancreatic neoplasms.

    Yamaguchi J, Yokoyama Y, Kokuryo T, Ebata T, Nagino M

    Surgery today   Vol. 48 ( 1 ) page: 9 - 17   2018.1

     More details

  76. Single-Incision Laparoscopic Splenectomy for an Unruptured Aneurysm of the Splenic Artery.

    Toyoda Y, Igami T, Ochiai Y, Ebata T, Yokoyama Y, Sugawara G, Mizuno T, Yamaguchi J, Nagino M

    Medical principles and practice : international journal of the Kuwait University, Health Science Centre   Vol. 27 ( 1 ) page: 95 - 98   2018

     More details

  77. Successful local treatment for repeated hepatic recurrences of cholangiolocellular carcinoma: a report on a long-term survivor.

    Shinohara K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Shimoyama Y, Shiina S, Tateishi R, Arano T, Nagino M

    Surgical case reports   Vol. 3 ( 1 ) page: 120   2017.12

     More details

  78. Occult mucin-producing cholangiocarcinoma in situ: a rare clinical case with difficult tumour staging.

    Kiriyama M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M

    Surgical case reports   Vol. 3 ( 1 ) page: 6   2017.12

     More details

  79. Long-term survival after multidisciplinary therapy for residual gallbladder cancer with peritoneal dissemination: a case report.

    Kuga D, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M

    Surgical case reports   Vol. 3 ( 1 ) page: 76   2017.12

     More details

  80. Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan

    Maeda O., Yokoyama Y., Yamaguchi J., Ota A., Matsuoka A., Morita S., Inoue M., Mizutani T., Shimokata T., Urakawa H., Mitsuma A., Nagino M., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 28   page: 69 - 69   2017.11

     More details

  81. Clinical influence of preoperative factor XIII activity in patients undergoing pancreatoduodenectomy.

    Watanabe N, Yokoyama Y, Ebata T, Sugawara G, Igami T, Mizuno T, Yamaguchi J, Nagino M

    HPB : the official journal of the International Hepato Pancreato Biliary Association   Vol. 19 ( 11 ) page: 972 - 977   2017.11

     More details

  82. The novel tumor suppressor Trefoil Factor Family 1 (TFF1) inhibits the development of hepatocellular carcinoma in mice

    Yamaguchi Junpei, Yokoyama Yukihiro, Kokuryo Toshio, Ebata Tomoki, Nagino Masato

    HEPATOLOGY   Vol. 66   page: 981A-982A   2017.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  83. Loss of trefoil factor 1 inhibits biliary regeneration but accelerates the differentiation of hepatic progenitors into hepatocytes in mice

    Hayashi Yuki, Yamaguchi Junpei, Kokuryo Toshio, Ebata Tomoki, Yokoyama Yukihiro, Nagino Masato

    HEPATOLOGY   Vol. 66   page: 378A - 379A   2017.10

     More details

  84. Inhibition of Toll-Like Receptor 4 Ameliorates Experimental Post-Ischemic Injury in the Cholestatic Liver through Inhibition of High-Mobility Group Box Protein B1 (HMGB1) Signaling

    Yokoi Tsuyoshi, Yokoyama Yukihiro, Kokuryo Toshio, Yamaguchi Junpei, Nagino Masato

    HEPATOLOGY   Vol. 66   page: 153A - 153A   2017.10

     More details

  85. Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer.

    Sunagawa M, Yamaguchi J, Kokuryo T, Ebata T, Yokoyama Y, Sugawara G, Nagino M

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]   Vol. 17 ( 5 ) page: 782 - 787   2017.9

     More details

  86. Study on the segmentation of the right anterior sector of the liver.

    Kobayashi T, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M

    Surgery   Vol. 161 ( 6 ) page: 1536 - 1542   2017.6

     More details

  87. Pulmonary Metastasis After Resection of Cholangiocarcinoma: Incidence, Resectability, and Survival.

    Yamada M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M

    World journal of surgery   Vol. 41 ( 6 ) page: 1550 - 1557   2017.6

     More details

  88. Novel therapy for pancreatic fistula using adipose-derived stem cell sheets treated with mannose.

    Kaneko H, Kokuryo T, Yokoyama Y, Yamaguchi J, Yamamoto T, Shibata R, Gotoh M, Murohara T, Ito A, Nagino M

    Surgery   Vol. 161 ( 6 ) page: 1561 - 1569   2017.6

     More details

    Language:English  

    DOI: 10.1016/j.surg.2016.12.022

    PubMed

  89. The development of an automatically produced cholangiography procedure using the reconstruction of portal-phase multidetector-row computed tomography images: preliminary experience.

    Hirose T, Igami T, Koga K, Hayashi Y, Ebata T, Yokoyama Y, Sugawara G, Mizuno T, Yamaguchi J, Mori K, Nagino M

    Surgery today   Vol. 47 ( 3 ) page: 365 - 374   2017.3

     More details

  90. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: A propensity score matching analysis of resectable perihilar cholangiocarcinoma.

    Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M

    Surgery   Vol. 161 ( 2 ) page: 394 - 404   2017.2

     More details

  91. The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer.

    Murata Y, Kokuryo T, Yokoyama Y, Yamaguchi J, Miwa T, Shibuya M, Yamamoto Y, Nagino M

    Anticancer research   Vol. 37 ( 2 ) page: 589 - 598   2017.2

     More details

  92. Surgery-Related Muscle Loss and Its Association with Postoperative Complications After Major Hepatectomy with Extrahepatic Bile Duct Resection.

    Otsuji H, Yokoyama Y, Ebata T, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M

    World journal of surgery   Vol. 41 ( 2 ) page: 498 - 507   2017.2

     More details

  93. Anatomic features of independent right posterior portal vein variants: Implications for left hepatic trisectionectomy.

    Watanabe N, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M

    Surgery   Vol. 161 ( 2 ) page: 347 - 354   2017.2

     More details

  94. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis.

    Mizuno T, Ebata T, Yokoyama Y, Igami T, Sugawara G, Yamaguchi J, Nagino M

    Surgery today   Vol. 47 ( 2 ) page: 182 - 192   2017.2

     More details

  95. Different Clinical Characteristics Between Distal Cholangiocarcinoma and Pancreatic Head Carcinoma With Biliary Obstruction

    Yokoyama Yukihiro, Ebata Tomoki, Igami Tsuyoshi, Sugawara Gen, Mizuno Takashi, Yamaguchi Junpei, Nagino Masato

    PANCREAS   Vol. 46 ( 10 ) page: 1322 - 1326   2017

  96. The Benefit of Extended Radical Surgery for Incidental Gallbladder Carcinoma Reviewed

    Junpei Yamaguchi, Yuji Kaneoka, Atsuyuki Maeda, Yuichi Takayama, Shunsuke Onoe and Masatoshi Isogai

    Surgery Today   Vol. 46   page: 453-459   2016

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  97. Positive surgical margins in surgically resected unifocal and multifocal IPMN Reviewed

    Junpei Yamaguchi, Yuji Kaneoka, Atsuyuki Maeda, Yuichi Takayama, Shunsuke Onoe and Masatoshi Isogai

    International Journal of Surgery   Vol. 28   page: 51-55   2016

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  98. Pancreatic duct gland (PDGs) are a progenitor compartment responsible for pancreatic ductal epithelial repair Reviewed

    Junpei Yamaguchi, Andrew S. Liss, Alexandra Sontheimer, Mari Mino-Kenudson, Carlos Fernandez-del Castillo, Andrew L. Warshaw, Sarah P. Thayer

    Stem Cell Research   Vol. 15   page: 190-202   2015

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  99. The role of histone deacetylase (HDAC) and EZH2 in oncogenesis: epigenetic silencing of tumor supressors Invited Reviewed

    Junpei Yamaguchi, Motoko Sasaki and Yasuni Nakanuma

    Tumor Suppressors     page: 149-160   2011

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  100. Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescencerelated lesion induced by lysolecithin Reviewed

    Junpei Yamaguchi, Motoko Sasaki, Kenichi Harada, Yoh Zen, Yasunori Sato, Hiroko Ikeda, Keita Itatsu, Yukihiro Yokoyama, Hisami Ando, Tetsuo Ohta, Akio Kubota, Koichi Shimizu, Yuji Nimura, Masato Nagino and Yasuni Nakanuma

    laboratory investigation   Vol. 89   page: 1018-1031   2009

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  101. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma Reviewed

    Junpei Yamaguchi, Motoko Sasaki, Yasunori Sato, Keita Itatsu, Kenichi Harada, Yoh Zen, Hiroko Ikeda, Yuji Nimura, Masato Nagino and Yasuni Nakanuma

    Cancer Science   Vol. 101 ( 2 ) page: 355-362   2009

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  102. 化学放射線療法による寛解導入後に胃癌が発見された2症例 Invited Reviewed

    山口淳平、片井均、佐野武、深川剛生、阪眞、井上昌也、笹子三津留、谷口浩和

    日本消化器外科学会雑誌   Vol. 41 ( 9 ) page: 1682-1685   2008

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  103. Spontaneous regression of inflammatory pseudotumor of the liver: three case reports Reviewed

    Junpei Yamaguchi, Yoshihiro Sakamoto, Tsuyoshi Sano, Kazuaki Shimada, Tomoo Kosuge

    surgery today   Vol. 37 ( 6 ) page: 525-529   2007

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  104. 高アルドステロン血症と耐糖能異常を合併した若年者肝細胞癌の一例 Invited Reviewed

    山口淳平、佐野力、島田和明、阪本良弘、奈良聡、小菅智男

    日本消化器外科学会雑誌   Vol. 40 ( 5 ) page: 611-616   2007

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  105. A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinacal response Reviewed

    Junpei Yamaguchi, Sadako Akashi-Tanaka, Takayoshi Fukutomi, Takayuki Kinoshita, Eriko Iwamoto, Miyuki Takasugi

    Breast Cancer   Vol. 13 ( 1 ) page: 100-103   2006

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  106. A case of mucinous cystic tumor of the pancreatic tail Reviewed

    Junpei Yamaguchi, Yoshihiro Sakamoto

    Japanese Journal of Clinical Oncology   Vol. 36 ( 1 ) page: 65   2006

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  107. Poorly differentiated hepatocellular carcinoma with unusual tubular structures Reviewed

    Junpei Yamaguchi, Hidenori Ojima, Nobuyoshi Hiraoka, Tadashi Hasegawa

    Journal of Clinical Pathology   Vol. 58   page: 1342   2005

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

▼display all

Presentations 30

  1. Trefoil Factor Family 1 (TFF1) Inhibits Epithelial-mesenchymal Transition and Enhances the Chemosensitivity of Pancreatic Ductal Adenocarcinoma (PDAC) International conference

    J. Yamaguchi, T. Kokuryo, Y. Yokoyama, T. Ebata, and M. Nagino

    APA annual meeting  2019.11 

     More details

    Event date: 2019.11

    Language:English   Presentation type:Oral presentation (general)  

    Country:United States  

  2. Trefoil Factor Family 1 (TFF1) Inhibits Epithelial-mesenchymal Transition and Enhances the Chemosensitivity of Pancreatic Ductal Adenocarcinoma (PDAC)

    2021.2 

     More details

    Event date: 2021.2

    Language:English   Presentation type:Oral presentation (general)  

  3. 膵腫瘍上皮由来癌関連線維芽細胞(CAF)と抗癌剤抵抗性の関係

    山口淳平、江畑智希、横山幸浩、國料俊男、梛野正人

    日本膵臓学会大会  2021.1 

     More details

    Event date: 2021.1

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

  4. 膵癌/何処から来て何処へ行くのか Invited

    山口淳平

    若手膵臓研究会  2020.11.4 

     More details

    Event date: 2020.11

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

  5. IPMNの発生起源と発癌機序

    山口淳平、横山幸浩、江畑智希、國料俊男、梛野正人

    日本膵臓学会大会  2019.7 

     More details

    Event date: 2019.7

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

  6. TFF1による膵発癌抑制機構の検討

    山口淳平、江畑智希、横山幸浩、國料俊男、伊神剛、水野隆史、尾上俊介、渡辺伸元

    日本外科学会定期学術集会  2019.4 

     More details

    Event date: 2019.4

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

  7. Trefoil Factor 1 inhibits epithelial-mesenchymal transition (EMT) of pancreatic intraepithelial neoplasm. International conference

    Junpei Yamaguchi, Yukihiro Yokoyama, Toshio Kokuryo and Masato Nagino

    AACR Pancreatic cancer: advances in science and clinical care  2018.9 

     More details

    Event date: 2018.9

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  8. The novel tumor suppressor Trefoil Factor Family 1 (TFF1) inhibits the development of hepatocellular carcinoma in mice International conference

    Junpei Yamaguchi, Yukihiro Yokoyama, Toshio Kokuryo and Masato Nagino

    AASLD the Liver Meeting 2017  2017.10 

     More details

    Event date: 2017.10

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  9. 遺伝子改変マウスを用いたTFF1欠損による膵浸潤癌発生に関する検討

    山口淳平、江畑智希、横山幸浩、國料俊男、梛野正人

    第48回日本膵臓学会大会  2017.7 

     More details

    Event date: 2017.7

    Language:Japanese   Presentation type:Oral presentation (general)  

  10. Preserved expression of TFF1 in invasive front is a poor prognostic factor in PDAC International conference

    Junpei Yamaguchi, Masaki Sunagawa, Yukihiro yokoyama, Toshio Kokuryo, Tomoki Ebata, Masato Nagino

    Joint Congress of The 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association & The 29th Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery  2017.6 

     More details

    Event date: 2017.6

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  11. TFF1 (Trefoil Factor Family 1) act as tumor suppressor to inhibit invasive transformation of PanIN into PDAC in vivo International conference

    Junpei Yamaguchi, Yukihiro Yokoyama, Toshio Kokuryo and Masato Nagino

    47th APA annual meeting 

     More details

    Event date: 2016.10

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  12. The tumor suppressive role of TFF (Trefoil Factor Family) in pancreatic carcinogenesis International conference

    Junpei Yamaguchi, Yukihiro Yokoyama, Toshio Kokuryo and Masato Nagino

    20th meeting of IAP, 6th meeting of AOPA 

     More details

    Event date: 2016.8

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  13. TFF (Trefoil Factor Family) is a novel tumor suppressor and can be the therapeutic target for pancreatic cancer International conference

    Junpei Yamaguchi, Yukihiro Yokoyama, Toshio Kokuryo and Masato Nagino

    An AACR Special Conference on Pancreatic Cancer 

     More details

    Event date: 2016.5

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  14. TFF1 (Trefoil Factor Family 1) act as tumor suppressor to prevent invasive transformation of pancreatic cancer International conference

     More details

    Event date: 2016.2

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  15. 膵癌に対するTrefoil Factor Family 2 (TFF2)の抗腫瘍効果の検討 International conference

    山口淳平、S.P. Thayer, A.L. Warshaw、江畑智希、横山幸弘、國料俊男、伊神剛、菅原元、水野隆司、梛野正人

    日本消化器外科学会総会 

     More details

    Event date: 2015.7

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  16. 膵癌抑制因子としてのTrefoil Factor Family 1 (TFF1)の役割の検討 International conference

    山口淳平、江畑智希、横山幸弘、國料俊男、伊神剛、菅原元、水野隆司、梛野正人

    日本肝胆膵外科学会学術集会 

     More details

    Event date: 2015.6

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

  17. Trefoil Family Factor 2 (TFF2)抑制による膵IPMN発生マウスモデルの検討 International conference

    山口淳平、S.P. Thayer, A.L. Warshaw、江畑智希、横山幸弘、國料俊男、梛野正人

    日本外科学会定期学術集会 

     More details

    Event date: 2015.4

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  18. Trefoil Factor Family 1 (TFF1) Inhibit the Invasion of Tumor Cells of the Pancreas International conference

    Junpei Yamaguchi, Toshio Kokuryo, Yukihiro Yokoyama and Masato Nagino

    Experimantal Biology 2015 

     More details

    Event date: 2015.3 - 2015.4

    Language:English   Presentation type:Oral presentation (general)  

    Country:United States  

  19. 当院におけるIPMN切除例55例の治療成績の検討

    山口淳平、磯谷正敏、原田徹、金岡祐次、亀井桂太郎、前田敦行、高山祐一、川勝章司、大塚新平、森治樹、米川佳彦、掘米香世子、渡辺夕樹、千馬耕亮

    日本肝胆膵外科学会 

     More details

    Event date: 2014.6

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

  20. 当院におけるIncidental Gallbladder Carcinomaに対する追加切除とその予後の検討

    山口淳平、磯谷正敏、原田徹、金岡祐次、亀井桂太郎、前田敦行、高山祐一、川勝章司、大塚新平、森治樹、米川佳彦、掘米香世子、渡辺夕樹、千馬耕亮

    日本臨床外科学会総会 

     More details

    Event date: 2013.11

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

  21. Loss of TFF2 in Pancreatic Duct Glands (PDG) results in the formation of IPMN suggesting TFF2 may function as tumor suppressor. International conference

     More details

    Event date: 2013.10 - 2013.11

    Language:English   Presentation type:Oral presentation (general)  

    Country:United States  

  22. Pancreatic Duct Glands (PDG), a Progenitor Stem Cell Niche Responsible for Pancreatic Epithelial Renewal and Repair in Response to Inflammatory Injury International conference

     More details

    Event date: 2012.10 - 2012.11

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  23. Pancreatic Duct Glands (PDG) Are the Origin of Gastric-Type IPMN International conference

     More details

    Event date: 2012.5

    Language:English   Presentation type:Oral presentation (general)  

    Country:United States  

  24. Pancreatic Duct Glands (PDG), a Progenitor Stem Cell Niche Responsible for Pancreatic Epithelial Renewal International conference

     More details

    Event date: 2011.11

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  25. Pancreati Duct Glands (PDG) Are the Origin of Gastric-type IPMN International conference

     More details

    Event date: 2011.11

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  26. 膵胆管合流異常症胆嚢における前癌病変と細胞老化機構の関与

    山口淳平、佐々木素子、原田憲一、佐藤保則、池田博子、梛野正人、中沼安二

    日本外科学会定期学術集会 

     More details

    Event date: 2010.4

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  27. ヒストン脱アセチル化酵素阻害剤(SAHA)およびEZH2抑制による胆嚢癌増殖抑制効果

    山口淳平、佐々木素子、原田憲一、佐藤保則、池田博子、梛野正人、中沼安二

    日本胆道学会学術集会 

     More details

    Event date: 2009.9

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  28. 胆嚢前癌病変における細胞老化機構の関与

    山口淳平、佐々木素子、原田憲一、佐藤保則、池田博子、板津慶太、梛野正人、中沼安二

    日本胆道学会学術集会 

     More details

    Event date: 2008.9

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  29. 胆嚢前癌病変における細胞老化の関与

    山口淳平、佐々木素子、原田憲一、佐藤保則、池田博子、中沼安二

    日本病理学会総会 

     More details

    Event date: 2008.5

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

  30. 高アルドステロン血症と耐糖能異常を合併した若年者肝細胞癌の一例

    山口淳平、佐野力、島田和明、阪本良弘、奈良聡、小菅智男

    日本消化器外科学会定期学術総会 

     More details

    Event date: 2006.7

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 21

  1. 胆道癌における融合型ノンコーディングRNAの機能解明と臨床応用

    Grant number:22K08820  2022.4 - 2025.3

    科学研究費助成事業  基盤研究(C)

    國料 俊男, 江畑 智希, 横山 幸浩, 山口 淳平, 砂川 真輝

      More details

    Authorship:Coinvestigator(s) 

    融合型ノンコーディングRNA(融合型ncRNA)はタンパク合成をしないにもかかわらず、多くの遺伝子制御に関与し、生体内で重要な役割を果たしている。また融合遺伝子が癌の機能や制御に関与していることも報告されている。われわれは胆管癌での全ゲノム解析により、異なる2つのノンコーディングRNAからなる融合型ncRNAを十数種類同定した。融合型ncRNAの存在は未知のメカニズムの存在を示唆しており、融合遺伝子同様にノンコーディングRNAの機能不全や異常シグナルの活性化など癌化への関与が考えられる。融合型ncRNAの機能解析により関連遺伝子など未知の癌化メカニズムを解明し新規癌治療戦略を構築する。

  2. 消化器外科手術後感染性合併症を予防するプロバイオティクス製剤の開発

    Grant number:21K08731  2021.4 - 2024.3

    科学研究費助成事業  基盤研究(C)

    横山 幸浩, 山口 淳平, 渡辺 伸元, 江畑 智希, 國料 俊男

      More details

    Authorship:Coinvestigator(s) 

    われわれは先行研究で、周術期にプロバイオティクスを使用することにより、術後感染性合併症発生が抑制されることを確認してきた。われわれがプロバイオティクスとして使用したものはLactobacillus casei ShirotaおよびBifidobacterium breve Yakultであったが、これらがプロバイオティクス製剤として最善のものであるかについては不明である。ヒトの腸内には術後感染性合併症をより強く抑制する菌が存在する可能性がある。本研究では、高度侵襲外科手術後の合併症を最も強力に抑制する腸内細菌種を、無菌マウスにヒトの腸内細菌叢を移植したモデルを用いて探索することを目的にする。
    本研究の目的は、高度侵襲消化器外科手術を受ける患者の術前を採集し、まず術後の感染合併症の発症と術前腸内細菌叢プロファイルの関連を探索することを第一としている。これまで名古屋大学医学部附属病院で、大量肝切除術、食道亜全摘術、膵頭十二指腸切除術、腹腔動脈幹合併切除を伴う膵体尾部切除術などを受ける患者から約500例の術前糞便検体を採集した。現在、これらの検体を解析し、糞便中有機酸濃度をHPLC法で、腸内細菌叢プロファイルを細菌特異的リボゾーマルRNAをターゲットにしたRT-PCR法で解析している。また、特定の検体に対しては次世代シーケンサーを用いて、さらに異なる視点からの菌叢解析も進めている。これらのデータと術後感染性合併症を含めた経過を表す様々な因子との相関を調べ、術前腸内細菌叢プロファイルと術後合併症発生との関連を調べている。一部の解析では、特定の便中有機酸濃度プロファイルが食道亜全摘術や、消化管再建を必要とする高度侵襲肝胆膵外科手術の術後感染性合併症と有意な相関があることを見出しており、このメカニズムを解明するためにさらに詳しく解析をすすめている。また、これらの解析から、特定の腸内細菌が術後の経過に及ぼす可能性についても探索してゆく予定である。最終的には、術前腸内細菌叢プロファイルを改善することにより、術後の感染性合併症をできるだけ減らし、周術期に使用する抗菌薬を可能な限り減らすことを目指す。今後もさらに糞便採集および便解析を進めてゆく予定である。
    症例の集積は順調に行なえており、並行して糞便の解析も行っている。まだ論文としては公表していないが、既に一部の結果を学会発表レベルで報告している。
    一部の解析で特定の便中有機酸濃度プロファイルが術後感染性合併症と有意な相関があることを見出しており、このメカニズムを解明するためにさらに詳しく解析をすすめている。本研究内容がさらに発展すれば、術前腸内細菌プロファイルを改善することにより、術後感染性合併症を減らすことができる可能性がある。最終的には、術前腸内環境を整えるための新規プロバイオティクス製剤開発が可能になるかもしれない。

  3. Whole genome sequencing concerning the chemoresistance of bile duct cancer

    Grant number:21K08796  2021.4 - 2024.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

  4. The mechanisms of early dissemination and tumor dormancy of pancreatic cancer

    Grant number:20H03751  2020.4 - 2025.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

      More details

    Authorship:Principal investigator 

    Grant amount:\17810000 ( Direct Cost: \13700000 、 Indirect Cost:\4110000 )

  5. Novel treatment using adipose stem cell for postoperative liver damage

    Grant number:19K09118  2019.4 - 2022.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    ONOE Shunsuke

      More details

    Authorship:Coinvestigator(s) 

    Adipose stem cell sheets have no side effect, such as ascites retention or infection in the mouse model of 30% hepatectomy and partial hepatectomy. Angiogenesis was increased in the sheet in time dependent manner. A fluorescent-labeled human adipose stem cells were identified on the liver side of the mouse. Interestingly, a large number of mouse cells were observed in the human adipose stem cell sheet. These results suggest that bidirectional migration between human adipose stem cells and mouse cells is involved in liver regeneration using a human adipose stem cell sheet.

  6. Novel diagnostic methods for invisible pancreas cancer

    Grant number:19K09168  2019.4 - 2022.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    WATANABE Nobuyuki

      More details

    Authorship:Coinvestigator(s) 

    Exosomes isolated from KLM1 (human pancreatic cancer cell line), were involved in the proliferation and motility. Angiogenesis array revealed the several proteins concerning angiogenesis and motility in exosomes of KLM1. However, these proteins were not identified in bile exosomes. Since KLM1 is a cell line derived from human pancreatic cancer and bile is derived from biliary tract cancer patients, the results were considered to be due to the difference in cancer type. Although further investigation is required, the identified proteins may be markers of pancreatic cancer-specific exosomes.

  7. The role of Trefoil Factors in hepato-carcinogenesis

    Grant number:19K09141  2019.4 - 2022.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Ebata Tomoki

      More details

    Authorship:Coinvestigator(s) 

    We found that TFF1 inhibited Wnt/b-catenin pathway and suppress the development of hepatocellular carcinoma. TFF1 inhibited the proliferative activity and promoted apoptosis of hepatocellular carcinoma cells in vitro, and TFF1-deficient mice developed frequent hepatocellular carcinoma. On the other hand, we found that TFF2 activated PTEN pathway and suppress the development of cholangiocellular carcinoma. TFF2 inhibited the proliferative activity and promoted apoptosis of cholangiocellular carcinoma cells, and TFF2-deficient mice developed frequent BilIN and cholangiocellular carcinoma. These results revealed that each TFF functioned as tumor suppressor in hepato-carcinogenesis.

  8. Novel therapy based on engraftment, asymmetric division and Self-organization of circulating tumor cells

    Grant number:19K09142  2019.4 - 2021.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

  9. Novel nucleic acid medicine for the fusion genes in cholangiocarcinoma

    Grant number:18H02879  2018.4 - 2022.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    Nagino Masato

      More details

    Authorship:Coinvestigator(s) 

    In the metachronous cholangiocarcinoma, the gene mutation in the secondary lesion has additional gene mutations to the gene mutation in the primary lesion, and their accumulations were considered to be one of the causes of the carcinogenesis in cholangiocarcinoma. Analysis of breakpoint on the coding region of the gene as somatic gene structure, demonstrated that total number is 3499 (3326-3655), the DEL (deletion) number is 2678 (2620-2781), the INV (inversion) number is 152 (136-170), INS (insertion) number 384 (364-406), DUP (tandem duplication) number 225 (192-253), and BND (breakend, interchromosomal translocation) number 58 (42-71). In addition, we revealed somatic structural variations on 320 genes, which detected in patients of the bile duct cancer in the GDC portal.
    These somatic structural variations were considered to be involved in the carcinogenesis of bile duct cancer.

  10. Development of real-time navigation system for hepatectomy

    Grant number:18K08644  2018.4 - 2021.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    IGAMI TSUYOSHI

      More details

    Authorship:Coinvestigator(s) 

    We are going to try development of real-time navigation system for laparoscopic hepatectomy, which resembles a car navigation system. Mean FRE of initial 5 patients was 17.7mm (range, 12.2 to 24.3 mm). First improvement was that MDCT were taken using radiological markers for registration of body parts. Mean FRE of the 8 patients who utilized first improvement was 10.2mm (range, 6.5 to 16.5 mm) and decreased (p = 0.014). Second improvement was that a micro magnetic sensor as an intraoperative body position sensor was fixed on the right-sided chest wall and meant that pre- and post- operative FRE was similar due to an intraoperatively automatic correction of gap of body position. Preoperative and postoperative mean FRE of the 8 patients who utilized second improvement were 11.1mm (range, 9.6 to 13.9 mm) and 10.1mm (range, 6.0 to 12.2mm). Those mean FRE were statistically similar (p = 0.250).

  11. The mechanisms of cancer development from Barrett esophagus regarding Trefoil Factors.

    Grant number:18K08699  2018.4 - 2021.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Fukaya Masahide

      More details

    Authorship:Coinvestigator(s) 

    The risk factor for esophageal adenocarcinoma is Barrett's epithelium and it is of great importance to clarify the mechanisms of its carcinogenesis to invent novel therapeutic treatment for esophageal adenocarcinoma. We evaluated surgically resected human esophageal cancer specimen and TFF-deficient mice to investigate the role of TFF in Barrett's epithelial carcinogenesis. We found that adenocarcinoma developed from Barrett's epithelium in TFF1-deficient mice, and that transcription of TFF1 gene was suppressed by DNA methylation in human esophageal adenocarcinoma. These results suggest that TFF1 functions as tumor suppressor to inhibit the development of esophageal adenocarcinoma. The novel treatment for esophageal adenocarcinoma by TFF1 can be anticipated.

  12. Novel therapy for cancer using deep ultraviolet

    Grant number:18K08673  2018.4 - 2021.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Miyata Kazushi

      More details

    Authorship:Coinvestigator(s) 

    Deep UV (DUV) irradiation altered cell morphology and induced apoptosis in cancer cell lines. CHK1, TLK1, and MRE11 were involved in the cellular events, and suppression of TLK1 and MRE11 enhanced apoptosis by DUV irradiation. In xenograft mouse model, DUV treatment suppressed tumor growth. Administration of the TLK1 inhibitor enhanced the antitumor effect of DUV treatment and reduced the expression of Ki67 in the tumor. In DUV exposure to gastric mucosa of pig, defect and erosion were identified. However, healed after 1 week. There are no abnormalities in pathological examination or blood biochemical examination. Further investigation was required for clinical application. However, our results demonstrated efficiency of DUV irradiation in cancer. This study suggests novel therapies using deep UV irradiation for cancer.

  13. The role of TFF1 to inhibit the development of pancreatic cancer

    Grant number:17K10695  2017.4 - 2020.3

    Yamaguchi Junpei

      More details

    Authorship:Principal investigator 

    Grant amount:\4550000 ( Direct Cost: \3500000 、 Indirect Cost:\1050000 )

    Trefoil Factor Family 1 is the secreted protein and supposed to be the tumor suppressor in gastric carcinogenesis. We analyzed surgically-resected pancreatic specimen, pancreatic cancer cell line and genetically-engeneered mouse model to investigate the association of TFF1 and pancreatic carcinogenesis. This study revealed that TFF1 inhibits malignant transformation of pancreatic premelignant lesions by controling epithelial-mesenchymal transition (EMT). TFF1 has the potential to be the novel therapeutic strategy for pancreatic cancer.

  14. 術後肝障害に対するTLR4を標的にした予防治療法の開発

    Grant number:17K10667  2017.4 - 2018.3

    菅原 元

      More details

    Authorship:Coinvestigator(s) 

    肝切除術後に発生する肝障害は重篤化することも多く早急に解決しなければいけない課題である。TLR4は免疫反応や炎症の制御に関わる分子であるToll様受容体の1つである。グラム陰性菌の外膜の成分であるリポ多糖(LPS)やグラム陽性菌のペプチドグリカン層にあるリポテイコ酸をリガンドとして認識する受容体である。ラット肝障害モデルへのTLR4阻害剤投与は肝機能を改善させ、肝障害を軽減させる傾向があった。一方で細胞株に対するTLR4阻害剤の研究において、TLR4阻害剤には細胞の増殖抑制効果を認めた。
    これまでの肝再生に関する研究において、肝障害時にTFF1(trefoil factor family1)の発現に変化が生じており、TFF1(trefoil factor family1)と胆管再生の関連性が示唆されている。われわれはTFF1(trefoil factor family1)をノックアウトしたマウスを作成しており、このTFF1をノックアウトしたマウスを用いてラット肝虚血・再潅流モデル、ラット胆管結紮による閉塞性黄疸モデル、CCl4(四塩化炭素)によるラット肝硬変モデルを作製した。ラット胆管結紮による閉塞性黄疸モデルでは、術後早期に死亡しており、正常マウス群と比較してTFF1のノックアウトマウス群での死亡率が高かった。また病理学的検討によりTFF1のノックアウトマウス群において胆管新生に抑制傾向を認めた。さらにTFF1のノックアウトマウス群の肝臓では有意に壊死組織の面積が多かった。CCl4(四塩化炭素)によるラット肝硬変モデルにおいて3か月の経過観察をおこなっているが、正常マウス群と比較して死亡率に関して特に差を認めなかった。

  15. Novel strategies for cancer stem cells

    Grant number:16K10454  2016.4 - 2019.3

    TSUNODA NOBUYUKI

      More details

    Authorship:Coinvestigator(s) 

    Proliferation was activated in c-Met-positive cholangiocarcinoma cells compared with that in c-Met-negative cholangiocarcinoma cells. Cell viability was suppressed in c-Met-positive and CD49f-positive cholangiocarcinoma cells. Cell growth was more highly activated in CD133-positive colorectal cancer cells than in CD133-negative colorectal cancer cells.
    Next-generation sequencing revealed 938 candidate fusion genes in cancer cells. LOC646214, which is a p21 protein (Cdc42/Rac)-activated kinase 2 pseudogene, formed fusions with many genes.
    In addition, long intergenic/intervening noncoding RNA (LINC) formed fusions with many genes. Because these fusion genes do not synthesize proteins, antibody medicines were not effective against these genes. From this viewpoint, these fusion genes were thought to be the best targets for nucleic acid medicines.

  16. Novel strategies to target the premetastatic niche for cancer metastasis

    Grant number:16K10568  2016.4 - 2019.3

    MIZUNO TAKASHI

      More details

    Authorship:Coinvestigator(s) 

    TPX2 was highly expressed in pancreatic cancer cell lines (PANC1 and KLM1) and colon cancer cell lines (DLD1 and HCT15). A TPX2 siRNA induced the TPX2 suppression and MCP1 overexpression in PANC1 and KLM1 cells. The culture medium of TPX2 siRNA-transfected pancreatic cancer cells showed an inhibitory effect on the proliferation and invasion of cancer cells. Factors secreted by TPX2 siRNA-transfected pancreatic cancer cells may cause a secondary effect on pancreatic cancer.
    Pre-exposure to 5-FU significantly enhanced its anticancer effect on the proliferation of KLM1, KP4 and DLD1 cells. However, there were no significant differences in the motility and invasion between cells that were and were not pre-exposed to 5-FU. The secondary effect was not simple and uniform in terms of cancer cell damage. Further investigations will be required for clinical applications. However, our data indicate the potential for a new therapy using TPX2 siRNA to improve the cancer prognosis.

  17. Mechanism of a new cancer treatment targeting TLR7

    Grant number:16K10531  2016.4 - 2019.3

    UEHARA KEISUKE

      More details

    Authorship:Coinvestigator(s) 

    Imiquimod, a TLR7 agonist, suppressed proliferation, motility and invasion and induced cell death in a human cancer cell line (DLD1, KLM1, Panc1 and HuCCT1). The cell morphology was different in each cancer cell line after imiquimod treatment. In addition, imiquimod induced early apoptosis in the cancer cell lines after 12 hours of treatment. Immunoglobulin heavy chain-binding protein (BiP), which is a marker of endoplasmic reticulum stress, was highly expressed in cancer cells after imiquimod treatment. Therefore, endoplasmic reticulum stress was considered a cause of imiquimod-induced apoptosis. However, the expression of PKR-like ER kinase (PERK), which is another marker of endoplasmic reticulum stress, did not change. This result suggested that a mechanism different from endoplasmic reticulum stress was involved in imiquimod-induced apoptosis. Further investigations will be required for clinical applications.

  18. Analysis of the inhibitory effect of cysteine on liver damage

    Grant number:16K10567  2016.4 - 2019.3

    YOKOYAMA YUKIHIRO

      More details

    Authorship:Coinvestigator(s) 

    Cysteine suppressed the shrinkage of hepatic stellate cells and strongly inhibited the endothelin-induced elevation of calcium in hepatic stellate cells. The serum ALT level in the cysteine-administered group was significantly lower than that in the non-administered group in a rat sepsis model. Cysteine showed an inhibitory effect on rat liver damage caused by intraperitoneal administration of lipopolysaccharide (LPS). The serum albumin level was correlated with the area of the psoas major muscle. The hospitalization period was prolonged, and postoperative complications such as an abdominal abscess and liver failure increased in patients with decreased muscle mass (sarcopenia) of the total femoral muscle. Most covalent bonds in cysteine were formed with serum albumin. Our results suggested that cysteine was effective in improving sarcopenia after surgery.

  19. Mechanism of action of a bisabolol derivative and its clinical application

    Grant number:16K10591  2016.4 - 2019.3

    KOKURYO TOSHIO

      More details

    Authorship:Coinvestigator(s) 

    Bisabolol derivative suppressed proliferation, motility and invasion and induced cell death in human pancreatic cancer cell lines. Gene analysis revealed that the expression of focal adhesion kinase (FAK) in cancer cell lines was decreased by bisabolol treatment. In addition, bisabolol derivative and bisabolol significantly inhibited the tumor growth in a mouse xenograft tumor model. Bisabolol demonstrated a similar antitumor effect to that of gemcitabine upon application of a novel drug delivery system using capsules. Although bisabolol was measured in rat blood using a mass spectrograph, the pharmacokinetics of the drug was not evaluated. Further investigations will be required for clinical applications. However, this study suggests that novel therapies using bisabolol for treating refractory cancer could be efficacious.

  20. Novel strategies targeting RAGE for postoperative infectious complications

    Grant number:15K10092  2015.4 - 2018.3

    FUKAYA MASAHIDE

      More details

    Authorship:Coinvestigator(s) 

    Severe liver damage was identified in rats with bile duct ligation and liver ischemia re-perfusion. RAGE (Receptor for advanced glycation end products) was highly expressed in these rats. TAK242, a TLR4 inhibitor, suppressed the elevation of serum ALT and AST in the rats with bile duct ligation and liver ischemia re-perfusion. In addition, TAK242 treatment decreased the area of hepatic necrosis and suppressed the expression of IL-1β, IL-6 and HMGB1. TAK242 significantly improved the severity of the liver damage caused by bile duct ligation and liver ischemia re-perfusion. However, the compound was not able to significantly suppress RAGE expression. In addition, bisabolol did not demonstrate an inhibitory effect against RAGE in rats with bile duct ligation and liver ischemia re-perfusion. Further investigations will be required for clinical applications. However, this study suggests that novel therapies using TAK242 for treating severe liver damage could be efficacious.

  21. 膵癌に対する腫瘍抑制因子としてのTFF2の検討

    2014.4 - 2016.3

    科学研究費補助金  研究活動スタート支援

      More details

    Authorship:Principal investigator 

    膵癌は難治性の悪性疾患であり、手術を含めた各種抗癌治療をもってしても予後不良である。
    本研究は膵癌に対する新たな治療法の開発を目的としており、なかでもTFF2(Trefoil Family Factor 2)の腫瘍抑制遺伝子としての作用と有用性を検討することである。

▼display all